KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 103 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $312,108 | +7.0% | 32,410 | 0.0% | 0.00% | – |
| Q2 2023 | $291,690 | +44.4% | 32,410 | +26.1% | 0.00% | – |
| Q1 2023 | $202,002 | +16.3% | 25,700 | 0.0% | 0.00% | – |
| Q4 2022 | $173,732 | -29.9% | 25,700 | +50.6% | 0.00% | – |
| Q3 2022 | $248,000 | +66.4% | 17,064 | +13.0% | 0.00% | – |
| Q2 2022 | $149,000 | -2.6% | 15,100 | +45.2% | 0.00% | – |
| Q1 2022 | $153,000 | -5.0% | 10,400 | -14.8% | 0.00% | – |
| Q4 2021 | $161,000 | -24.4% | 12,200 | 0.0% | 0.00% | – |
| Q3 2021 | $213,000 | -27.1% | 12,200 | 0.0% | 0.00% | – |
| Q2 2021 | $292,000 | -18.2% | 12,200 | -35.1% | 0.00% | – |
| Q4 2020 | $357,000 | +44.0% | 18,800 | -4.6% | 0.00% | – |
| Q3 2020 | $248,000 | +4.2% | 19,700 | 0.0% | 0.00% | – |
| Q2 2020 | $238,000 | +153.2% | 19,700 | +60.2% | 0.00% | – |
| Q1 2020 | $94,000 | -47.8% | 12,300 | +21.8% | 0.00% | – |
| Q4 2019 | $180,000 | +53.8% | 10,100 | 0.0% | 0.00% | – |
| Q3 2019 | $117,000 | – | 10,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |